<html><head></head><body><h1>Nalmefene</h1><p class="drug-subtitle"><b>Class:</b> Opiate Antagonists<br/>
- Antidotes<br/>
<b>VA Class:</b> CN102<br/>
<b>Chemical Name:</b> (5α)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylene-morphinan-3,14-diol hydrochloride<br/>
<b>Molecular Formula:</b> C<sub>21</sub>H<sub>25</sub>NO<sub>3</sub>•HCl<br/>
<b>CAS Number:</b> 58895-64-0<br/>
<b>Brands:</b> Revex</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h2>Introduction</h2><p>Synthetic opiate antagonist.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Nalmefene</h2><h3>Postoperative Opiate Depression</h3><p>Treatment of opiate-induced depression, including respiratory depression, caused by natural and synthetic opiates.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Opiate Overdosage</h3><p>Management of known or suspected opiate overdosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Nalmefene Dosage and Administration</h2><h3>Administration</h3><p>Principally administered by IV injection; can be administered by IM or sub-Q injection if venous access cannot be established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For reversal of postoperative opiate depression, administer blue-labeled commercially available injection containing 100 mcg/mL nalmefene.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For management of known or suspected opiate overdose, administer green-labeled commercially available injection containing 1 mg/mL nalmefene.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p><i>Proper steps should be taken to prevent use of incorrect concentration of injection.</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer as an IV bolus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>When used for treatment of postoperative opiate-induced depression in patients with increased cardiovascular risk, it may be desirable to dilute to a final ratio of 1:1 in 0.9% sodium chloride injection or sterile water for injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cardiovascular Disease under Cautions.)</p><h3>Dosage</h3><p>Available as nalmefene hydrochloride; dosage expressed in terms of nalmefene.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Titrate dosage to reverse opiate-induced effects; when adequate opiate reversal has been established, additional doses of nalmefene are not required and may cause unwanted reversal of analgesia or precipitate withdrawal.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initially, 0.25 mcg/kg given at 2- to 5-minute intervals until the desired response is obtained.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patient Weight</p><p>Initial Dosage (0.25 mcg/kg)</p><p>Volume of Nalmefene 100 mcg/mL Solution (Blue-label) to Administer</p><p>50 kg</p><p>12.5 mcg</p><p>0.125 mL</p><p>60 kg</p><p>15 mcg</p><p>0.15 mL</p><p>70 kg</p><p>17.5 mcg</p><p>0.175 mL</p><p>80 kg</p><p>20 mcg</p><p>0.2 mL</p><p>90 kg</p><p>22.5 mcg</p><p>0.225 mL</p><p>100 kg</p><p>25 mcg</p><p>0.25 mL</p><p>Cumulative total dosage &gt;1 mcg/kg does not provide additional therapeutic effect.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patients at increased cardiovascular risk: Initially, 0.1 mcg/kg given at 2- to 5- minute intervals until desired response is obtained.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Opiate naive patients: Initially, 7.14 mcg/kg (0.5 mg/70 kg), followed by a second dose of 14.29 mcg/kg (1 mg/70 kg) 2–5 minutes later, if necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If no response is observed after a total dose of 21.43 mcg/kg (1.5 mg/70 kg), additional doses are unlikely to provide therapeutic effect.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patients suspected of opiate dependency: Initially, 1.43 mcg/kg (100 mcg/70 kg).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If no withdrawal is observed within 2 minutes, 7.14 mcg/kg (0.5 mg/70 kg), followed by 14.29 mcg/kg (1 mg/70 kg) 2–5 minutes later, if necessary;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; observe closely for withdrawal symptoms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If recurrence of respiratory depression occurs, titrate dosage incrementally to response to avoid over-reversal.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Cumulative dosage &gt;1 mcg/kg does not provide additional therapeutic effect.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Cumulative dosages ≥21.43 mcg/kg (1.5 mg/70 kg) unlikely to increase therapeutic response.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>Decreased clearance; however, dosage adjustment not required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Decreased clearance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Dosage adjustment not required, however, administer incremental doses slowly (e.g., over 60 seconds) to minimize hypertension and dizziness associated with rapid administration in such patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage adjustment not required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Nalmefene</h2><h3>Contraindications</h3><ul>
<li>
<p>Known hypersensitivity to nalmefene or any ingredient in the formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Known hypersensitivity to nalmefene or any ingredient in the formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>When used in emergency settings, other resuscitative measures (e.g., maintenance of an adequate airway, artificial respiration, administration of oxygen, vasopressor agents) should be readily available and used first when necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of recurrent respiratory depression in postoperative and overdose patients after initial response to nalmefene.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Carefully monitor patients who have responded to nalmefene since the duration of action of some opiates (e.g., methadone and levo-alpha-acetylmethadol [LAAM]) may exceed that of nalmefene; monitor patients until there is no reasonable risk of recurrent respiratory depression.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Serious adverse cardiovascular effects (e.g., VT and VF, pulmonary edema, hypertension, hypotension, cardiovascular instability) reported in postoperative patients and in emergency department settings following administration of nalmefene; may be associated with excessive doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with preexisting cardiovascular disease or in those receiving potentially cardiotoxic drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Reduced dosage recommended in postoperative patients at high risk for cardiovascular complications.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Adults under Dosage and Administration.)</p><p>Possible precipitation of acute withdrawal symptoms.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use with extreme caution in patients with known physical dependence on opiates or following surgery involving high doses of opiates.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Observe patients suspected of opiate dependency for symptoms of withdrawal following initial and subsequent nalmefene injections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Incomplete reversal of buprenorphine-induced analgesia reported in animal models; therefore, nalmefene may not completely reverse buprenorphine-induced respiratory depression.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible risk of seizures.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category B.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Distributed into milk in rats; not known whether distributed into human milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use caution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy not established in children &lt;18 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy not established in neonates, however, nalmefene may be used in the resuscitation of neonates when benefits outweigh the risks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Special Populations under Pharmacokinetics.)</p><p>Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and potential for concomitant disease and drug therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Decreased clearance; however, dosage adjustments not recommended because nalmefene is administered as an acute course of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Decreased clearance; administer dosages slowly to minimize adverse effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Renal Impairment under Dosage and Administration.)</p><h3>Common Adverse Effects</h3><p>Nausea, vomiting, tachycardia, hypertension.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Nalmefene</h2><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Anesthetics, inhalational</p><p>No deleterious interactions observed when nalmefene was administered after inhalation anesthetics&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Benzodiazepines</p><p>No deleterious interactions observed when nalmefene was administered after benzodiazepines&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Flumazenil</p><p>Risk of seizures&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Skeletal muscle relaxants</p><p>No deleterious interactions observed when nalmefene was administered after skeletal muscle relaxants&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Skeletal muscle relaxant antagonists</p><p>No deleterious interactions observed when nalmefene was administered after skeletal muscle relaxant antagonists and general anesthesia&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Nalmefene Pharmacokinetics</h2><h3>Absorption</h3><p>Completely absorbed following IM or sub-Q administration; mean bioavailability is about 101.5% and 99.7%, respectively.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Therapeutic plasma concentrations occurred 5–15 minutes following administration of a single IM or sub-Q dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Duration of opiate antagonist activity is variable and depends on the dose, the half-life and plasma concentration of opiate being reversed, the presence or absence of other drugs affecting the brain or muscles of respiration, and the dose of nalmefene being administered.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Effects persist for not &gt;30–60 minutes following administration of a partial reversing dose (i.e., 1 mcg/kg).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Effects may persist for several hours following administration of a full reversing dose (i.e., 1 mg/70 kg).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Rapidly distributed following IV administration, with 80% of brain opiate receptors blocked within 5 minutes of administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Distributed into milk in rats; not known whether distributed into human milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>45%.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Metabolized in the liver, primarily by glucuronide conjugation to nalmefene glucuronide, an inactive metabolite.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Excreted principally in urine, mainly as metabolites, and in feces (17%).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Biphasic; terminal half-life is approximately 10.8 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In patients with end-stage renal disease, clearance of nalmefene is reduced by 25–27% compared with that in healthy adults and half-life is increased to around 26.1 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In patients with hepatic impairment, clearance of nalmefene is reduced by 28.3%.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In geriatric patients, no substantial differences in clearance, steady-state volume of distribution, or half-life relative to younger adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>15–30 ºC.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Actions</h2><ul>
<li>
<p>A long-acting opiate antagonist.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Antagonizes the effects of opiates (e.g., respiratory depression, sedation, hypotension).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>In patients who have <i>not</i> recently received opiates, nalmefene exerts no pharmacologic effect.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Does not produce tolerance, physical dependence, or have abuse potential.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; May precipitate acute withdrawal in individuals physically dependent on opiates.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>A long-acting opiate antagonist.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antagonizes the effects of opiates (e.g., respiratory depression, sedation, hypotension).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In patients who have <i>not</i> recently received opiates, nalmefene exerts no pharmacologic effect.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Does not produce tolerance, physical dependence, or have abuse potential.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; May precipitate acute withdrawal in individuals physically dependent on opiates.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information. (See Cautions.)</p>
</li>
</ul><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information. (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection</p><p>100 mcg (of nalmefene) per mL</p><p>Revex<sup></sup></p><p>Baxter</p><p>1 mg (of nalmefene) per mL</p><p>Revex<sup></sup></p><p>Baxter</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions February 1, 2008. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><h2>References</h2><p>1. Ohmeda Pharmaceuticals. Revex<sup></sup> (nalmefene hydrochloride) injection prescribing information. Library Corner, NJ; 1996 Mar.</p><p>a. Baxter Healthcare Corporation. Revex<sup></sup> (nalmefene hydrochloride) injection prescribing information. Decatur, IL; 2006 May.</p><p>b. Baxter Healthcare Corporation, Round Lake; IL: Personal communication.</p><h2>More about nalmefene</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: antidotes</li>
</ul><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Opioid Overdose</li>
<li>Reversal of Opioid Sedation</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>